Cingulate Inc. (CING)
About Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Net income
- -$22.4M
- Total assets
- $15.1M
- Market cap
- $62.5M
Source: SEC EDGAR · updated Jun 8, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $62.5M
- Shares outstanding
- 12.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 8, 2021
Cingulate Inc. (CING) Stock Price
- Reported a net loss of $22.4M.
- Trading 57% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cingulate Inc..
Write a review
News about Cingulate Inc.
News & sentiment via Polygon.io
Cingulate Inc.: frequently asked questions
Is Cingulate Inc. an American company?
Cingulate Inc. is a US-based company headquartered in Kansas City, Kansas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Cingulate Inc. headquartered?
Cingulate Inc. is headquartered in Kansas City, Kansas, United States.
Is Cingulate Inc. publicly traded?
Yes — Cingulate Inc. is a publicly traded company. Its stock trades under the ticker symbol CING on the NASDAQ.
What does Cingulate Inc. do?
Cingulate Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
